Amyloid-beta peptide (Aβ)
The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?
... 3. Amyloid beta peptide is (synapto)toxic over a wide range of ...Lipid-derived amyloid beta peptide (Aβ) oligomers cause learning and memory impairments in ...
14
Intracellular distribution of amyloid beta peptide and its relationship to the lysosomal system
... Background: Amyloid beta peptide (A β ) is the main component of extraneuronal senile plaques typical of Alzheimer ’ s disease (AD) brains. Although A β is produced by normal neurons, it is shown to ...
7
Amyloid beta peptide degradation in cell cultures by mycoplasma contaminants
... Background: Cell cultures have become an indispensable tool in Alzheimer's disease research for studying amyloid-β (Aβ) metabolism. It is estimated that up to 35% of cell cultures in current use are infected with ...
6
Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide
... acyl peptide hydro- lase as an enzyme that degrades ...Aβ peptide, the APEH enzyme that was purified from transfected cells was incu- bated with synthetic Aβ 1–40 for 5 ...Aβ peptide and its ...Aβ ...
10
Differential effects of amyloid-beta peptide aggregation status on <em>in vivo</em> retinal neurotoxicity
... Abstract: The present study examined the relationship between amyloid beta (Aβ)-peptide aggregation state and neurotoxicity in vivo using the rat retinal–vitreal model. Following single unilateral ...
17
Human Gastrokine 1 and its anti-amyloidogenic properties
... of amyloid- beta peptide (Aβ) and to interact with the C-terminal region of APP thus hindering the γ-secretase proteolytic ...Indeed, amyloid is of great medical importance since it originates ...
6
Mitochondrial β amyloid in Alzheimer's disease
... Aβ, amyloid-beta peptide; ABAD, amyloid-binding alcohol dehydrogenase; AD, Alzheimer’s disease; ANT, adenine nucleotide translocase; Cdk5, cyclin-dependent kinase 5; CHANA, cyclohexenyl amine ...
11
The immunotherapy of Alzheimer's disease
... the amyloid beta peptide and/or by increasing its clear- ance from the ...of amyloid beta peptide would follow the inhibition of the beta and gamma secretases, enzymes ...
7
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease
... : amyloid beta-peptide; AD: Alzheimer ’ s disease; APP: amyloid precursor protein; APPsw: Swedish familial Alzheimer ’ s disease mutant isoform of APP: BACE: beta-APP cleaving enzyme; ...
21
Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease
... of amyloid deposition or decreased 18F-fluoro-2-deoxyglucose uptake or cerebrospinal fluid (CSF) analysis of amyloid beta peptide 1–42 (A β 42), tau and phosphorylated ...extracellular ...
14
Increased Caspase-6 activity in the human anterior olfactory nuclei of the olfactory bulb is associated with cognitive impairment
... increases amyloid beta peptide production [32, 36, ...mutant amyloid precursor protein (APP), three conditions associated with familial AD [11, 48], Casp6 is activated in the absence of Casp3 ...
13
Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report
... Results: This review identifies a large number of biochemical markers derived from CSF and blood. There is a considerable overlap of VCI-SSVD clinical symptoms with those of Alzheimer ’ s disease (AD). Although most of ...
12
Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimer’s disease
... For decades, therapies for Alzheimer’s disease (AD) have targeted beta-amyloid (Aβ) and phosphorylated tau pro- teopathies. Unfortunately, research has not yielded any viable therapeutics over the past 20 ...
9
Truncated and modified amyloid-beta species
... nicastrin and presenilin 1 or presenilin 2 [8]. The trans- membrane proteins presenilin 1 and presenilin 2 possess two critical aspartyl residues that are part of the catalytic domain of this γ-secretase subunit. The ...
9
Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs
... In late 2015, Novartis announced a global collaboration with Amgen to test a BACE inhibitor, CNP520, in hu- man trials and to develop further compounds from the pre-clinical BACE inhibitor programs of both companies. ...
11
Mechanisms of amyloid formation revealed by solution NMR
... of amyloid formation, giving rise to species of the same overall shape, but different in structural details, sufficient to make them toxic (or not toxic) to the ...key amyloid intermediates in atomistic ...a ...
19
The Effect of Professional Development on Middle School Teachers' Technology Integration: An Action Research Study
... With the projected global growth in AD over the next few decades [152], continued research into treatment methods is vital. While many of the current treatments have evolved from targeting the symptoms, epidemiological ...
131
Alzheimer disease therapy: Can the amyloid cascade be halted?
... a peptide with amyloidogenic properties (17, ...amyloidogenic peptide is linked to ...the amyloid cascade hypothesis ...as amyloid triggered a pathological cascade that ulti- mately produced ...
9
The Alzheimer’s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway
... of amyloid-β (Aβ) in amyloid deposits in AD brain and trans- genic animal models of AD [16, 19, ...and amyloid plaque accumulation in amyloid-β precursor protein (AβPP) transgenic mouse brain ...
13
Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
... the amyloid hypothesis, to a division of the population into four distinct groups (Figure 1A), which are: patients who are cognitively healthy (normal cognition, NC; Figure 1A, 4), patients who are cognitively ...
5